900 WEST PLATT STREET, SUITE 200, TAMPA, FL
Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Andriy Mushak Appointed Fractional CFO; Alan Weichselbaum Departs
Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease Study
Other Events
Telomir Pharmaceuticals Acquires TELI Pharmaceuticals for 34.4M Shares
Shareholders Approve Amendment to 2023 Omnibus Incentive Plan
Q1
FY 2025
Q3
Q2
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Certificate
Registration of Securities
Amended Registration Statement for Securities
Definitive Merger Proxy Statement
Additional Proxy Materials
PRER14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
PREM14A
Prospectus Filed Pursuant to Rule 424(b)(1)
Correspondence
Submission Upload